RARG and leukemia: They analyzed the prognostic impact of APL with alternative RARA or RARG fusions, showing that the 3-year overall survival (OS) and leukemia-free survival (LFS) of APL with alternative RARA or RARG were worse than that of PML-RARA cohort.